retatrutide trial duration treatment clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Significantly Reduces Visceral Fat – New Weight Loss Drug Retatrutide:

In the TRIUMPH-1 trial, Retatrutide's highest dose resulted in an average weight loss of 28.3% at 80 weeks, compared to tirzepatide's 20.9% in the SURMOUNT-1 trial

Accessed April 15, 2024.

Only interventional studies, specifically randomized controlled trials (RCTs), were included to ensure the highest quality of evidence for assessing efficacy and safety

GoalBMI Wellness provides dose titration management, side effect monitoring, and ongoing follow-up as standard, with insurance verification and transparent self-pay pricing

Princeton, NJ: Novo Nordisk Inc

The trigger, though, is usually the nutritional shortfall created by rapid weight loss rather than the chemical itself